Ipsen – January 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen nominates Peter Guenter to its Board of Directors

Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma

Ipsen – December 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen – Half year statement – 2025 12 31

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

IPSEN – Buy-back programme – Art 5 of MAR – Week 49- 2025

Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

IPSEN – Buy-back programme – Art 5 of MAR – Week 48 – 2025